Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.820 +0.140 (+8.33%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,005
Open 1.840
Bid (Size) 1.730 (300)
Ask (Size) 1.950 (300)
Prev. Close 1.680
Today's Range 1.820 - 1.840
52wk Range 1.170 - 2.630
Shares Outstanding 78,986,490
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
From Innate Pharma SA
Via Business Wire

Performance

YTD
N/A
N/A
1 Month
+1.1%
+1.1%
3 Month
+30.0%
+30.0%
6 Month
+2.2%
+2.2%
1 Year
-17.3%
-17.3%

More News

Read More
News headline image
Outcome of Innate Pharma’s 2026 Annual General Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to participate in the Jefferies Global Healthcare Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in the D. Boral Capital Global Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in the Kempen Life Sciences Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Reports Full Year 2025 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Releases Its 2026 Financial Calendar
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Present at Jefferies Global Healthcare Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Get insights into the top gainers and losers of Tuesday's pre-market session. ↗
Via Chartmill

Frequently Asked Questions

Is Innate Pharma S.A. - American Depositary Shares publicly traded?
Yes, Innate Pharma S.A. - American Depositary Shares is publicly traded.
What exchange does Innate Pharma S.A. - American Depositary Shares trade on?
Innate Pharma S.A. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Innate Pharma S.A. - American Depositary Shares?
The ticker symbol for Innate Pharma S.A. - American Depositary Shares is IPHA on the Nasdaq Stock Market
What is the current price of Innate Pharma S.A. - American Depositary Shares?
The current price of Innate Pharma S.A. - American Depositary Shares is 1.820
When was Innate Pharma S.A. - American Depositary Shares last traded?
The last trade of Innate Pharma S.A. - American Depositary Shares was at 07/29/26 03:59 PM ET
What is the market capitalization of Innate Pharma S.A. - American Depositary Shares?
The market capitalization of Innate Pharma S.A. - American Depositary Shares is 143.76M
How many shares of Innate Pharma S.A. - American Depositary Shares are outstanding?
Innate Pharma S.A. - American Depositary Shares has 144M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.